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Ras proteins regulate a wide range of biological pro-
cesses by interacting with a broad assortment of effector
proteins. Although activated forms of Ras are frequently
associated with oncogenesis, they may also provoke
growth-antagonistic effects. These include senescence,
cell cycle arrest, differentiation, and apoptosis. The
mechanisms that underlie these growth-inhibitory ac-
tivities are relatively poorly understood. Recently, two
related novel Ras effectors, NORE1 and RASSF1, have
been identified as mediators of apoptosis and cell cycle
arrest. Both of these proteins exhibit many of the prop-
erties normally associated with tumor suppressors. We
now identify a novel third member of this family, des-
ignated RASSF2. RASSF2 binds directly to K-Ras in a
GTP-dependent manner via the Ras effector domain.
However, RASSF2 only weakly interacts with H-Ras.
Moreover, RASSF2 promotes apoptosis and cell cycle
arrest and is frequently down-regulated in lung tumor
cell lines. Thus, we identify RASSF2 as a new member of
the RASSF1 family of Ras effectors/tumor suppressors
that exhibits a specificity for interacting with K-Ras.
The Ras family of oncoproteins is intimately involved in the
regulation of a wide variety of biological processes (1–3). This
versatility is facilitated by the ability of Ras proteins to interact
with a broad range of heterologous effector proteins (1, 4–6).
Although best known for their role in mitogenesis and onco-
genesis, Ras proteins can also promote growth arrest and cell
death (7–11). In contrast to the Ras pathways mediating mito-
genesis and transformation, those mediating growth-antago-
nistic effects remain relatively poorly characterized.
RASSF1 has recently been identified as a potential tumor
suppressor that can serve as a Ras effector (12, 13). RASSF1
can induce apoptosis or cell cycle arrest (12, 14) and is fre-
quently down-regulated by promoter methylation during tu-
morigenesis (15). NORE1 is related to RASSF1 and can also
induce a Ras-dependent apoptosis (16, 17). Like RASSF1,
NORE1 is frequently down-regulated in primary tumors and
tumor cell lines (17). Data base analysis suggests that there
may be more members of this family. We identified in the
GenBankTM data base a human RASSF1-like hypothetical pro-
tein that was originally designated KIAA0168 but now is being
referred to as RASSF2. We cloned the gene and sought to
determine whether RASSF2 is also a Ras effector/tumor sup-
pressor of the RASSF1 family.
We now report that RASSF2 can bind directly to K-Ras in a
GTP-dependent manner via the Ras effector domain. There-
fore, RASSF2 demonstrates the basic characteristics of a Ras
effector. The interaction of RASSF2 with Ras appears to be
specific to K-Ras, as only a weak interaction could be detected
with H-Ras.
Rather than promoting transformation, over-expression of
RASSF2 inhibits the growth of lung tumor cells. RASSF2-
mediated growth inhibition is enhanced by activated K-Ras
and appears to involve both apoptosis and cell cycle arrest.
Analysis of RASSF2 protein expression in a series of human
lung tumor cell lines shows that the protein is frequently down-
regulated. Thus, we show that RASSF2 is a new member of the
RASSF1 family and shares the properties of being a potential
Ras effector/tumor suppressor.
MATERIALS AND METHODS
Identification of RASSF2—RASSF2 was identified by performing a
tblastn search of the GenBankTM data base using the Ras association
(RA)1 domain of RASSF1 as a query. The human hypothetical protein
KIAA0168 was identified as a potential RASSF1-like protein. This
protein is now being referred to as RASSF2/Rasfadin (18), and we will
conform to this convention. Sequences were aligned using ClustalW.
DNA and Plasmids—RASSF2 was identified as IMAGE Consortium
clone 22950 distributed by the American Type Culture Collection
(ATCC; Manassas, VA). The RASSF2 coding region was PCR-cloned
using oligomers 5-ggatccatggactacagccaccaaac and 3-caattgtcagattgt-
tgctggggtc, which added a BamHI site to the 5 end and an MfeI site to
the 3 end. After sequencing to confirm fidelity, the gene was cloned into
pZIPHA, pCDNAF (17), and pEGFP (Clontech, Palo Alto, CA) as a
BamHI/MfeI fragment. The RA domain of RASSF2 (nucleotides 535–
789) was cloned as a BamHI/MfeI fragment into pMal (New England
BioLabs, Beverly, MA) and pGEX2T (Amersham Biosciences). Acti-
vated K-Ras was cloned into the BamHI site of pCGNHA (19), and
effector mutants were generated using a QuikChange kit (Stratagene,
La Jolla, CA).
Ras Binding Assays—In vivo assays were performed by transfecting
293-T cells with 5 g of each plasmid using LipofectAMINE 2000
(Invitrogen). After 48 h, the cells were lysed in modified radioimmune
precipitation assay buffer (20) and immunoprecipitated with HA beads
(Sigma). The immunoprecipitate was then subjected to Western analy-
sis with an anti-FLAG monoclonal (Sigma) to measure the co-precipi-
tation of RASSF2. In vitro binding assays were performed using puri-
fied GST fusion protein of the RA domain of RASSF2 and purified
K-Ras derived from baculovirus-infected Sf9 cells (a generous gift of D.
Stokoe, University of California, San Francisco, CA). K-Ras protein was
loaded with the GTP analog guanylyl-5-imidodiphosphate (Sigma) by
incubating in 100 mM Tris, pH 8, 50 mM NaCl, and 10 mM EDTA with
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6 mM GTP analog (Sigma) for 10 min at room temperature. The loaded
protein was then stabilized with 10 mM MgCl2. 2 pg of loaded protein
were then added to 100 ng of fusion protein on Sepharose beads in
phosphate-buffered saline with 1 protease inhibitors (Pharmingen), 5
mM MgCl2, 1 M ZnCl2, and 0.01% Tween 20. The proteins were rotated
at 4 °C for 1 h, washed three times, and then subjected to Western
analysis.
Growth Inhibition Assays—Cell lines were obtained from the ATCC.
A549 human lung carcinoma cells were transfected with 1 g of pZ-
IPHA RASSF2 or empty vector and selected in 500 g/ml of G418
(Invitrogen) for 2 weeks. Cells were fixed and stained with crystal
violet. Transient growth inhibition assays were performed in 293-T
cells by transfecting with LipofectAMINE 2000 (Invitrogen) as de-
scribed previously (12).
Apoptosis Assays—RASSF2-induced apoptosis was examined by us-
ing the pCaspase3-Sensor system (Clontech) and fluorescent micros-
copy to measure caspase-3 activation in individual live cells. This sys-
tem uses an enhanced yellow fluorescent protein (EYFP) fused with a
nuclear export signal and a nuclear localization signal. The nuclear
export signal is dominant and separated from the EYFP by a caspase-3
cleavage site. In the absence of active caspase-3, the EYFP localizes to
the cytosol. In the presence of active caspase-3, the nuclear export
signal is cleaved off, and the nuclear localization signal promotes trans-
port into the nucleus. Cells were transfected with 100 ng of pCaspase3-
Sensor and/or red fluorescent protein-RASSF2. After 24 h, red cells
were examined for the localization of EYFP. The detection of caspase-3
activation and induction of apoptosis using this method were quantified
by identifying and counting cells that co-expressed the nuclear localized
pCaspase3-Sensor protein and red fluorescent protein-RASSF2.
In situ trypan blue uptake was performed on 293 HEK cells (ATCC).
Cells were transfected with 5 g of RASSF2 in the presence or absence
of 50 ng of K-Ras12V. 72 h post-transfection trypan blue was added at
a final concentration of 0.04%. Dye uptake was quantitated by counting
the number of blue cells in three random 40 fields.
Fluorescence-activated Cell Sorting Analysis—Cell cycle analysis
was performed in 293-T cells transfected with 5 g of pEGFP empty
vector or pEGFP-RASSF2 using LipofectAMINE 2000 (Invitrogen). 24 h
after transfection cells were harvested and resuspended at a concen-
tration of 2  106 cells/ml in medium with low serum (2%). Hoechst
33342 (Sigma) was added to a final concentration of 3 g/ml and
incubated for 1 h at 37 °C. After incubation cells were immediately
centrifuged in the cold, resuspended to a final concentration of 1  106
cells/ml, and subjected to fluorescence-activated cell sorting analysis.
DNA content of GFP-positive cells was determined using a fluores-
cence-activated cell sorting Vantage S.E. (BD Biosciences). The soft-
ware programs CellQuest (BD Biosciences) and ModFit (Verity Soft-
ware House) were used for data acquisition and cell cycle modeling.
Northern Analysis—A commercial, prequantitated normal tissue blot
of mRNA was obtained from Clontech. The coding region of RASSF2
was used as a probe. Experiments were performed as described previ-
ously (12).
Assay of RASSF2 Protein Expression in Tumor Cell Lines—RASSF2
polyclonal antiserum was prepared to the peptide GLR-
RPIRLQMQDDNERIR (residues 61–78) by ResGen (Huntsville, AL)
and affinity-purified. The antibody did not cross-react with NORE1 or
RASSF1 (data not shown). Specificity was confirmed by peptide com-
petition experiments (data not shown). The antibody was then used at
a dilution of 1/1000 to perform Western analysis of a series of human
lung tumor cell lines.
RESULTS
Sequence Comparison of Human RASSF2, RASSF1, and
NORE1—Sequences were aligned using ClustalW (Fig. 1). The
RA domain is boxed in Fig. 1 and shows 28% identity to that of
RASSF1A and 31% identity to that of NORE1. RASSF2 lacks
the cysteine-rich domain of NORE1 and RASSF1A.
Binding of K-Ras to RASSF2—To determine whether Ras
and RASSF2 could interact, we first performed co-transfection
experiments in 293-T cells with FLAG-tagged RASSF2 and
HA-tagged activated and wild type K-Ras. After 48 h, cells were
lysed and immunoprecipitated with HA-Sepharose beads (Sig-
ma) for 1 h. After washing, the immunoprecipitate was sub-
jected to Western analysis using an anti-FLAG antibody. Fig.
2a (top) shows that RASSF2 preferentially precipitates with
activated K-Ras. The relative quantities of Ras and RASSF2 in
the lysate were determined by immunoblotting the lysate with
HA and FLAG (Fig. 2a, bottom). We next determined if the
interaction required the effector domain of Ras by using a
similar strategy with a series of effector mutants of K-Ras.
Figure 2b (top) shows that mutations in the effector domain of
K-Ras severely impair the ability of the protein to bind
RASSF2. Again, a Western blot of the lysates before immuno-
precipitation is shown at the bottom of Fig. 2b. Finally, we
examined the possibility that RASSF2 might preferentially
bind K-Ras over H-Ras. In Fig. 2c we show that although
activated K-Ras readily precipitated RASSF2, the levels of
FIG. 1. Alignment of RASSF2 with
RASSF1 and NORE1. Amino acid com-
parison of human RASSF2 (GenBankTM
NM_014737), human NORE1 (GenBankTM
NM_031437), and human RASSF1A (Gen-
BankTM AF102770). Alignments were gen-
erated using the ClustalW algorithm. Iden-
tical and similar amino acids within the RA
domains are boxed and shaded in gray and
dark gray, respectively. The percent iden-
tity between the RA domains of RASSF2
and RASSF1A is 28%, and the percent
identity calculated between RASSF2 and
NORE1 is 31%.
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RASSF2 precipitating with activated H-Ras were barely detect-
able. Protein levels in the lysate are again shown at the bottom
of Fig. 2c.
To confirm that the K-Ras-RASSF2 interaction is direct, we
prepared recombinant GST fusion protein of the RA domain of
RASSF2. This was used as an affinity reagent to precipitate
purified, farnesylated K-Ras (generous gift of D. Stokoe, Uni-
versity of California, San Francisco, CA). Fig. 3a shows that the
RASSF2-RA domain fusion protein can precipitate farnesyl-
ated K-Ras from solution. Equal loading of GST fusion protein
was confirmed by Western blotting of a sample of the precipi-
tate with an anti-GST antibody (Fig. 3b) (Santa Cruz Biochemi-
cals, Santa Cruz, CA). Note that the GST-RA domain fusion
protein construct also produced GST. Similar results were ob-
tained with a maltose-binding protein fusion of the RASSF2 RA
FIG. 4. Deregulated RASSF2 expression promotes cell death.
A549 cells were transfected with RASSF2 in the selectable vector
pZIPHA (pZipVector). Cells were selected in G418, and colonies were
stained with crystal violet. RASSF2-transfected cells (pZipRassF2) did
not survive.FIG. 2. K-Ras4B binds RASSF2 in a GTP-dependent manner
via the effector domain. HA-tagged K-Ras4B proteins (wild type
(WT), activated, and effector mutants) and FLAG-tagged RASSF2 were
co-expressed in 293-T cells. The lysates were immunoprecipitated (IP)
with HA and then immunoblotted (IB) using FLAG. Pre-precipitated
lysates were examined by Western blot using HA and FLAG to deter-
mine the relative levels of each protein before precipitation (shown at
the bottom in each panel). a, RASSF2 preferentially precipitates acti-
vated K-Ras4B12V compared with the wild type protein. b, effector
domain mutants of activated K-Ras4B are impaired for binding
RASSF2. A RASSF2-transfected cell lysate serves as the positive con-
trol (Pos. ct.). c, RASSF2 exhibits a strong preference for binding
K-Ras4B12V over H-Ras12V.
FIG. 3. RASSF2 and K-Ras interact directly. A GST-RASSF2-RA
domain fusion protein was prepared (GST-F2RA), and 100 ng was used
as an affinity reagent to precipitate a solution of purified, farnesylated
K-Ras4B loaded with a non-hydrolyzable GTP analog. a, K-Ras was
identified by Western analysis using sc-135 anti-K-Ras polyclonal an-
tibody (Santa Cruz Biotechnology). b, levels of GST and GST-F2RA
were confirmed by Western analysis with polyclonal antiserum specific
for GST (Santa Cruz Biotechnology).
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domain (data not shown). Therefore, RASSF2 binds directly to
K-Ras in a GTP-dependent manner via the effector domain.
RASSF2 Expression Inhibits Cell Growth—RASSF2 was
cloned into a selectable expression vector, pZIPHA, and trans-
fected into A549 human lung carcinoma cells. Cells were se-
lected for 2 weeks and then stained with crystal violet (Fig. 4).
Cells transfected with RASSF2 failed to generate colonies,
whereas the vector alone gave a virtually confluent plate.
As we were unable to generate stable cell lines expressing
RASSF2, we resorted to transient transfections to determine
the effects of Ras on RASSF2-mediated growth inhibition.
293-T cells were transfected with RASSF2  activated Ras and
examined after 48 h (Fig. 5). At this time point, modest growth
inhibition was detected with the RASSF2 alone, but this was
dramatically enhanced by the presence of activated K-Ras.
Interestingly, H-Ras had little effect on this activity. To deter-
mine whether the growth inhibition by RASSF2 was apoptotic
in nature and whether the presence of activated Ras enhanced
this process, we transfected 293 cells with RASSF2 
K-Ras12V. 72 h post-transfection we added trypan blue directly
to the cells and quantitated dead cells by dye uptake. Fig. 6
shows that RASSF2 on its own promotes modest cell death, but
in the presence of activated K-Ras cell death is enhanced.
Quantification is shown in Fig. 6b.
RASSF2 Promotes Apoptosis and Cell Cycle Arrest—To de-
termine the mechanistic basis of the RASSF2-mediated growth
inhibition, we used the pCaspase3-Sensor system (Clontech)
and fluorescent microscopy to measure caspase-3 activation in
individual cells. Cells were co-transfected with pCaspase3-Sen-
sor and red fluorescent protein-RASSF2. After 24 h, red cells
were examined for the localization of EYFP. Fig. 7a shows that
in vector-transfected cells the EYFP remained cytosolic. How-
ever, in RASSF2-co-transfected cells, the majority of cells
showed nuclear localization of EYFP, hence demonstrating
caspase-3 activation and apoptosis. The results are quantified
in Fig. 7b.
We also performed cell cycle assays on GFP-RASSF2-trans-
fected 293-T cells. Fig. 8 demonstrates that GFP-RASSF2-
expressing cells consistently show an 20% decrease in the
G2/M phase of the cell cycle, suggesting that the cells tend to
arrest in the G0/G1 phase.
Expression of RASSF2 in Normal Tissue and Tumor
Cells—To determine the tissue specificity of RASSF2 we per-
formed Northern analysis on a commercial normal tissue
mRNA blot. A single transcript was detected at 5.4 kb in most
tissue. The signal was most intense in the brain, peripheral
blood, placenta, and lung samples (Fig. 9). To determine
whether RASSF2 might be down-regulated during tumorigen-
esis, we generated a RASSF2-specific polyclonal antibody. We
prepared lysates from a series of human lung tumor cell lines
and examined them for RASSF2 protein expression. A normal
bronchial epithelial cell line was used as a control. Western
analysis demonstrated that the RASSF2 protein was fre-
quently down-regulated in the human lung tumor cell lines
(Fig 10). Proliferating cell nuclear antigen was used as an
internal control for protein loading.
DISCUSSION
Although Ras oncoproteins are powerfully transforming in
many cellular systems (2, 5, 21), they may also provoke a
variety of growth-antagonistic effects including senescence (9),
apoptosis (10, 11), and cell cycle arrest (22). This capacity to
induce transformation or death is not unique to Ras but has
also been described for other key oncoproteins such as c-MYC
(23, 24). Thus, certain critical oncoproteins provide a close
FIG. 5. K-Ras4B enhances RASSF2-mediated growth inhibi-
tion. 293-T cells were transiently transfected with RASSF2  activated
K-Ras4B or H-Ras and examined after 48 h. At this time point, RASSF2
promoted a modest growth inhibition that was enhanced by the pres-
ence of activated K-Ras4B but not by the presence of activated H-Ras.
FIG. 6. RASSF2-mediated cell death is enhanced by K-Ras4B.
293 cells were transiently transfected with RASSF2  activated K-Ras.
Trypan blue was added after 72 h, and dye uptake was quantitated.
RASSF2 promotes a modest cell death that is enhanced in the presence
of activated K-Ras4B. a, in situ trypan blue staining of K-Ras12V,
RASSF2, K-Ras12V  RASSF2, and FAS. Dye uptake is enhanced
when RASSF2 is co-expressed with activated K-Ras. b, quantification of
the results in panel a.
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linkage between the processes of life and death. Which function
attains dominance in a particular cell after oncogene activation
will determine whether that cell extinguishes itself or
progresses to become a successful tumor. Understanding the
anti-oncogenic pathways mediated by oncogenes may provide
valuable alternative targets for therapeutics.
Ras pathways mediating growth inhibition and death are not
as well characterized as those used to promote mitogenesis and
transformation. However, the recent discovery of the NORE1-
RASSF1 class of Ras effectors has started to address this defi-
ciency. RASSF1 and NORE1 have been reported to mediate
Ras-dependent apoptosis as well as cell cycle arrest (12, 14, 16,
17). Not only do these proteins mediate growth inhibition, but
they are also frequently down-regulated during tumor devel-
opment. Moreover, reintroduction of the genes into tumor cell
lines results in a loss of tumorigenicity (13, 16, 17). Therefore,
these proteins have the potential to serve as tumor suppressors
that are directly activated by Ras. Loss of function of these
growth-inhibitory Ras-controlled pathways may prove as crit-
ical as gain of function of conventional Ras-controlled pathways
during tumor development. Bioinformatic data base analysis
suggests that there may be several other members of the
NORE1-RASSF1 family that remain uncharacterized. We have
now cloned and characterized RASSF2 to determine whether it
too serves as a Ras effector/tumor suppressor.
Examination of the Ras binding properties of RASSF2
showed that it would readily associate with farnesylated K-Ras
in a GTP-preferential manner. Moreover, the interaction was
direct as the purified RA domain bound purified, farnesylated
K-Ras4B. K-ras is the most commonly activated ras gene in
human tumors (25) and is the only ras gene that is essential for
embryonic development (26). Thus, it appears that K-Ras pro-
tein is functionally different from the other Ras isoforms and
has a special role in transformation and development. It has
been hypothesized that the reason for the special properties of
K-Ras is that there may be certain Ras effector proteins that
are particularly critical to tumorigenesis and development that
preferentially associate with K-Ras (27). However, although
differences in effector binding between the Ras isoforms have
been reported (28), these involved only a 2–3-fold difference in
binding activity. Here we see an almost complete preference for
K-Ras over H-Ras. Thus, RASSF2 could play a key role in
mediating some of the unique biological properties of K-Ras.
As we had found some difficulty in showing stable associa-
tion of RASSF2 with H-Ras, we manufactured the three classic
Ras effector mutants, E37G, T35S, and Y40C (29) in
K-Ras4B12V. Only the T35S mutant retained any ability to
interact with RASSF2, and this was rather weak. Thus, the
interaction of RASSF2 and K-Ras4B is via the Ras effector
domain. Hence, RASSF2 meets the basic requirements for a
potential Ras effector. Ras effector mutants have been used as
tools to identify the Ras pathways that are critical for tumor
development (30, 31). Interpreting the results of this type of
study should now take into account the potential loss of inter-
action with tumor suppressor effectors, such as RASSF2, as
well as the loss of interaction with oncoprotein effectors, such
as Raf-1.
The mechanism of action of the RASSF1 family of proteins
remains under investigation. Whereas RASSF1 and NORE1
have been shown to promote apoptosis in some cell types (12,
16, 17), Shivakumar et al. (14) suggest they cause cell cycle
arrest, not apoptosis, in others. Consequently, we decided to
examine both parameters for RASSF2. We found that RASSF2
promoted the activation of caspase-3 in COS-7 cells. A similar
effect was observed in 293-T cells (data not shown), but the
results were much clearer in the COS-7 cell type due to their
flatter morphology. Thus, RASSF2 can promote apoptosis. To
examine cell cycle effects, we used fluorescence-activated cell
sorting analysis of GFP-RASSF2 expressing 293-T cells. These
fast cycling cells showed a 20% decrease in the G2/M compo-
nent in three separate experiments. This suggests that the cells
are tending to arrest in G0/G1. Thus, RASSF2 can promote
apoptosis and cell cycle arrest.
A potential mechanism for NORE1-induced apoptosis was
recently identified by Khokhlatchev et al. (16) when it was
demonstrated that NORE1 binds to the pro-apoptotic kinase
MST1. However, they were unable to demonstrate that NORE1
activated the MST1 kinase activity (in fact, it appears to inhibit
it), and so although this is an intriguing observation, the role of
MST1 kinase in NORE1/RASSF1/RASSF2-mediated cell death
remains unclear.
Analysis of RASSF2 mRNA levels in normal tissue shows
considerable differential expression. Interestingly, some of the
FIG. 7. RASSF2 expression promotes apoptosis. COS-7 cells
were transfected with pCaspase3-Sensor EYFP  red fluorescent pro-
tein-RASSF2. a, panel A shows EYFP in the absence of RASSF2. Panel
B depicts the localization of EYFP, panel C shows RASSF2 expression
in the same cells, and panel D illustrates 4,6-diamidino-2-phenylindole
nuclear staining of the cells in panels B and C. In the RASSF2-positive
cells, the EYFP has translocated to the nucleus, demonstrating activa-
tion of caspase-3. b, detection of caspase-3 activation in RASSF2-ex-
pressing cells was quantified by counting cells showing relocalization of
the pCaspase3-Sensor protein. The data shown is the mean  S.D. of
two separate experiments.
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tissues which show the lowest levels of RASSF2 expression
(heart, kidney, and skeletal muscle) give among the highest
levels of RASSF1 expression in an identical blot (12). Both
genes show detectable levels of mRNA in normal lung tissue.
Analysis of RASSF2 expression in a panel of lung tumor cell
lines showed that the protein is expressed at modest levels in a
normal human bronchial epithelia cell line but fell to undetect-
able levels in most of the tumor cell lines examined. Intrigu-
ingly, one cell line, 441, showed very high levels of RASSF2
expression. This suggests that either there is a mutation in the
FIG. 8. RASSF2 promotes cell cycle arrest. Cells were transfected with pEGFP vector or pEGFP-RASSF2. 50,000 GFP-positive cells were
examined for each analysis, and the results shown here are the mean of three independent experiments. CV values were below 8%. A 20% decrease
in the G2/M phase was observed with RASSF2, suggesting that the cells are prone to arrest in G0/G1.
FIG. 9. Expression of RASSF2 mRNA in normal tissue. Northern analysis was performed using a commercially available normal multitissue
mRNA blot. RASSF2 is highly expressed in brain, placenta, peripheral blood, and lung. Skel. Mus., skeletal muscle; Small Intes., small intestine;
Periph. Bld., peripheral blood.
FIG. 10. RASSF2 protein expression is frequently down-regulated in human lung tumor cell lines. A RASSF2-specific polyclonal
antibody to RASSF2 was prepared and used to examine a series of lung tumor cell lines by Western analysis. A normal human bronchial epithelia
(NHBE) cell line was used as a positive control. Most lung tumor cell lines were negative for expression. The blot was reprobed with proliferating
cell nuclear antigen (PCNA) as a loading control.
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RASSF2 that renders it non-growth-inhibitory or that there is
a mutation in a downstream component of the RASSF2 path-
way that makes this cell line resistant to RASSF2-mediated
growth inhibition. These possibilities are currently being
investigated.
In summary, we now identify a third member of the RASSF1-
NORE1 family that preferentially binds K-Ras with the char-
acteristics of an effector. RASSF2 inhibits the growth of tumor
cells, and its growth-inhibitory properties are enhanced by
activated K-Ras. RASSF2 promotes both cell cycle arrest and
apoptosis; consequently, its down-regulation may play a key
role in the development of cancer.
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